Roula Qaqish

1.8k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Roula Qaqish is a scholar working on Emergency Medicine, Infectious Diseases and Virology. According to data from OpenAlex, Roula Qaqish has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Emergency Medicine, 6 papers in Infectious Diseases and 6 papers in Virology. Recurrent topics in Roula Qaqish's work include HIV-related health complications and treatments (7 papers), HIV Research and Treatment (6 papers) and Hepatitis B Virus Studies (5 papers). Roula Qaqish is often cited by papers focused on HIV-related health complications and treatments (7 papers), HIV Research and Treatment (6 papers) and Hepatitis B Virus Studies (5 papers). Roula Qaqish collaborates with scholars based in United States, France and United Kingdom. Roula Qaqish's co-authors include Todd T. Brown, Martin King, Barbara A. da Silva, Barry Bernstein, Grace A. McComsey, Mansoor M. Amiji, Vijay R. Patel, John Rublein, David J. Ritchie and Angela M. Nilius and has published in prestigious journals such as Gastroenterology, AIDS and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Roula Qaqish

17 papers receiving 1.4k citations

Hit Papers

Antiretroviral therapy and the prevalence of osteopenia a... 2006 2026 2012 2019 2006 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roula Qaqish United States 10 961 649 492 416 231 17 1.4k
Belinda Ha United States 15 801 0.8× 901 1.4× 209 0.4× 637 1.5× 172 0.7× 35 1.3k
Henning Drechsler United States 14 532 0.6× 614 0.9× 137 0.3× 382 0.9× 267 1.2× 25 1.0k
Beverly Alston‐Smith United States 13 610 0.6× 421 0.6× 73 0.1× 281 0.7× 329 1.4× 23 1.0k
Mark Bloch Australia 17 481 0.5× 669 1.0× 70 0.1× 391 0.9× 351 1.5× 40 1.5k
Paola Cicconi Italy 17 301 0.3× 489 0.8× 44 0.1× 369 0.9× 351 1.5× 45 881
Jean‐Philippe Chave Switzerland 16 474 0.5× 864 1.3× 21 0.0× 493 1.2× 499 2.2× 21 1.3k
J Falloon United States 7 430 0.4× 454 0.7× 20 0.0× 508 1.2× 400 1.7× 9 1.1k
Sasiwimol Ubolyam Thailand 22 374 0.4× 865 1.3× 14 0.0× 706 1.7× 463 2.0× 84 1.3k
Laurence Moachon France 10 142 0.1× 305 0.5× 11 0.0× 123 0.3× 126 0.5× 19 587
Jesús Santos Spain 16 365 0.4× 563 0.9× 4 0.0× 380 0.9× 226 1.0× 55 875

Countries citing papers authored by Roula Qaqish

Since Specialization
Citations

This map shows the geographic impact of Roula Qaqish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roula Qaqish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roula Qaqish more than expected).

Fields of papers citing papers by Roula Qaqish

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roula Qaqish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roula Qaqish. The network helps show where Roula Qaqish may publish in the future.

Co-authorship network of co-authors of Roula Qaqish

This figure shows the co-authorship network connecting the top 25 collaborators of Roula Qaqish. A scholar is included among the top collaborators of Roula Qaqish based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roula Qaqish. Roula Qaqish is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Coutré, Steven, Christopher F. Barnett, Olayemi Osiyemi, et al.. (2022). Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. Open Forum Infectious Diseases. 9(5). ofac104–ofac104. 6 indexed citations
3.
Asselah, Tarik, Christophe Hézode, Roula Qaqish, et al.. (2016). Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. ˜The œLancet. Gastroenterology & hepatology. 1(1). 25–35. 41 indexed citations
5.
Asselah, Tarik, Christophe Hézode, Roula Qaqish, et al.. (2016). 503 High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I). Gastroenterology. 150(4). S1037–S1037. 2 indexed citations
6.
Reynes, Jacques, Roger Trinh, Federico Pulido, et al.. (2012). Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study. AIDS Research and Human Retroviruses. 29(2). 256–265. 103 indexed citations
7.
Wyk, Jean van, Roula Qaqish, Ronald D’Amico, et al.. (2011). Meta-Analysis of Once-Daily and Twice-Daily Lopinavir/Ritonavir Combined with NRTIs in HIV-1-Infected, Antiretroviral-Naive Patients. Future Virology. 7(1). 103–113. 1 indexed citations
8.
Brown, Todd T., Grace A. McComsey, Martin King, et al.. (2009). Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(5). 554–561. 258 indexed citations
9.
Pham, Paul A., Craig W. Hendrix, Patricia Barditch‐Crovo, et al.. (2007). Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz. Antiviral Therapy. 12(6). 963–970. 6 indexed citations
10.
Gilliam, Bruce L., Kirk M. Chan‐Tack, Roula Qaqish, et al.. (2006). Successful Treatment with Atazanavir and Lopinavir/Ritonavir Combination Therapy in Protease Inhibitor-Susceptible and Protease Inhibitor-Resistant HIV-Infected Patients. AIDS Patient Care and STDs. 20(11). 745–759. 9 indexed citations
11.
Brown, Todd T. & Roula Qaqish. (2006). Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20(17). 2165–2174. 707 indexed citations breakdown →
12.
Qaqish, Roula, et al.. (2004). Bone Disorders Associated with the Human Immunodeficiency Virus: Pathogenesis and Management. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(10). 1331–1346. 12 indexed citations
13.
Qaqish, Roula, et al.. (2003). Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection. Clinical Therapeutics. 25(12). 3084–3099. 38 indexed citations
14.
Qaqish, Roula, et al.. (2003). Management of Anemia of Chronic Disease in Patients with the Human Immunodeficiency Virus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(11). 1475–1485. 7 indexed citations
15.
Robinson, Michael J. & Roula Qaqish. (2002). Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatric Clinics of North America. 25(1). 149–175. 10 indexed citations
16.
Qaqish, Roula, et al.. (2000). HIV‐Associated Lipodystrophy Syndrome. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(1). 13–22. 64 indexed citations
17.
Qaqish, Roula, et al.. (1999). Evaluation of the Factors Influencing Stomach-specific Delivery of Antibacterial Agents for Helicobacter pylori Infection. Journal of Pharmacy and Pharmacology. 51(6). 667–672. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026